User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 3 results.
    • Speech
    Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
    Raghav, Kanwal Pratap Singh Yoshino, Takayuki Guimbaud, Rosine Chau, Ian Van den Eynde, Marc[UCL] Maurel, Joan Tie, Jeanne Kim, Tae Won Yeh, Kun-Huei Barrios, Daniel Kobayashi, Kojiro Bako, Emarjola Aregay, Mehreteab Meinhardt, Gerold Siena, Salvatore (2021) 2021 ASCO Annual Meeting I —
    • Speech
    Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
    Raghav, Kanwal Pratap Singh Yoshino, Takayuki Guimbaud, Rosine Chau, Ian Van den Eynde, Marc[UCL] Maurel, Joan Tie, Jeanne Kim, Tae Won Yeh, Kun-Huei Barrios, Daniel Kobayashi, Kojiro Bako, Emarjola Aregay, Mehreteab Meinhardt, Gerold Siena, Salvatore (2022) 2022 ASCO Gastrointestinal Cancers Symposium —
    • Speech
    Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
    Raghav, Kanwal Pratap Singh Siena, Salvatore Takashima, Atsuo Kato, Takeshi Van den Eynde, Marc[UCL] Di Bartolomeo, Maria Komatsu, Yoshito Kawakami, Hisato Peeters, Marc Andre, Thierry Lonardi, Sara Yamaguchi, Kensei Tie, Jeanne Gravalos Castro, Cristina Strickler, John H Barrios, Daniel Yan, Qi Kamio, Takahiro Kobayashi, Kojiro Yoshino, Takayuki (2023) American Society of ClinicalOncology (ASCO)2023 — McCormick Place, 2301 S King Dr, Chicago, IL 60616, USA